

16<sup>th</sup> January 2006



**National Institute for  
Health and Clinical Excellence**

MidCity Place  
71 High Holborn  
London  
WC1V 6NA

Tel: +44 (0)20 7067 5800  
Fax: +44 (0)20 7067 5801  
nice@nice.org.uk

www.nice.org.uk

Dear Sir / Madam

**Health Technology Appraisal**

**Review of NICE Technology Appraisal Guidance No.61, on the use of  
capecitabine and tegafur with uracil for the treatment of metastatic colorectal  
cancer**

**Proposal to move guidance to the static list**

As you may be aware the planned date for review of the above guidance is January 2006.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

Having re-run the search strategy from the original assessment report the Institute has not found any relevant additions to the evidence base that would have a material effect on the guidance. Consequently we propose that the original guidance become static. The decision would be reviewed if there were changes in the marketing authorisation to extend the licensed indication for either of the drugs.

In order to be completely confident that this is appropriate, we are asking all original consultees, to inform us of any evidence which would suggest that a review would be beneficial. Please see appendix A for a full list of the organisations we have contacted.

I would be grateful if you could inform us of your views on the approach the Institute plans to take and of any evidence you believe relevant by 13<sup>th</sup> February 2006. Please send your comments by email to Bijal Chandarana, at <mailto:bijal.chandarana@nice.org.uk> or by phone at 020 7067 5919 or by post

National Institute for Health and Clinical Excellence  
Proposals for review on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer

Date: January 2006

to the above address. Please note that a summary table of all comments received will be published on the Institute's web site when a decision has been taken.

Information on this approach will be published on the Institute's website (<http://www.nice.org.uk/page.aspx?o=home>) on 23<sup>rd</sup> January 2006 and is confidential in the interim.

In the meantime if you have any queries please contact Bijal .

Yours faithfully

Dr Carole Longson  
Director, Centre for Health Technology Evaluation